Biogen BIIB
NASDAQ BIIB
$219.88 -2.94 (-1.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Biogen (BIIB) Gains from Sales and Divestitures (2010)

Updated

Biogen's Gains from Sales and Divestitures was $88.6 million in FY2024.

Analysis

Biogen (BIIB) Gains from Sales and Divestitures (2010) Analysis & Trends

  • The FY2024 figure marks the lowest annual Gains from Sales and Divestitures since FY2010.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $503.7 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Biogen 32.49 Bn 19.14 Bn 1.96 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2010 105,000.00
Sep 30, 2010 -1.36 Mn
API Access

Biogen Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BIIB&period=max&api_key=YOUR_API_KEY